Gene amplifications associated with the development of hormone- resistant prostate cancer

Article English OPEN
Edwards, J. ; Krishnan, S. ; Witton, C.J. ; Bartlett, J.M.S. (2003)
  • Publisher: American Association for Cancer Research
  • Subject: RC0254 | RB

Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential. \ud Experimental Design: We analyzed 38 paired (prehormone/posthormone resistance) prostate cancer samples using the Vysis GenoSensor. Archival microdissected tumor DNA was extracted, amplified, labeled, and hybridized to Amplione I DNA microarrays containing 57 oncogenes.\ud Results: Genetic instability increased during progression from hormone-sensitive to hormone-resistant cancer (P = 0.008). Amplification frequencies of 15 genes (TERC, MYBL3, HRAS, PI3KCA, JUNB, LAMC2, RAF1, MYC, GARP, SAS, FGFR1, PGY1, MYCL1, MYB, FGR) increased by greater than 10% during hormone escape. Receptor tyrosine kinases were amplified in 73% of cases; this was unrelated to development of hormone resistance. However, downstream receptor tyrosine kinase signaling pathways showed increased amplification rates in resistant tumors for the mitogen-activated protein kinase (FGR/Src-2, HRAS, and RAF1; P = 0.005) and phosphatidylinositol 3'-kinase pathways (FGR/ Src-2, PI3K, and Akt; P = 0.046). Transcription factors regulated by these pathways were also more frequently amplified after escape (MYC family: 21% before versus 63% after, P = 0.027; MYB family: 26 % before versus 53 % after, P = 0.18).\ud Conclusions: Development of clinical hormone escape is linked to phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. These pathways may function independently of the androgen receptor or via androgen receptor activation by phosphorylation, providing novel therapeutic targets.
  • References (62)
    62 references, page 1 of 7

    1. Sciarra, A., Casale, P., Colella, D., Di Chiro, C., and Di Silverio, F. Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. Scand. J. Urol. Nephrol, 33: 211-216, 1999.

    2. Dorkin, T. J., and Neal, D. E. Basic science aspects of prostate cancer. Semin. Cancer Biol., 8: 21-27, 1997.

    3. Culig, Z., Hobisch, A., Bartsch, G., and Klocker, H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc. Res. Tech., 51: 447- 455, 2000.

    4. Chang, C., Saltzman, A., Yeh, S., Young, W., Keller, E., Lee, H. J., Wang, C., and Mizokami, A. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr., 5: 97-125, 1995.

    5. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanern, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplificaiton of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401- 406, 1995.

    6. Linja, M. J., Savinainen, K. J., Saramaki, O. R., Tammela, T. L. J., Vessella, R. L., and Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61: 3550 -3555, 2001.

    7. Miyoshi, Y., Uemura, H., Fujinami, K., Mikata, K., Harada, M., Kitamura, H., Koizumi, Y., and Kubota, Y. Fluorescence in situ Hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate., 43: 225-232, 2000.

    8. Edwards, J., Krishna, N. S., Mukherjee, R., Watters, A. D., and Bartlett, J. M. S. Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. Br. J. Urol. Int., 88: 633- 637, 2001.

    9. Trapman, J., and Cleutjens, K. B. J. M. Androgen-regulated gene expression in prostate cancer. Semin. Cancer Biol., 8: 29 -36, 1997.

    10. Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem. Biophys. Res. Commun., 259: 21-28, 1999.

  • Metrics
    No metrics available
Share - Bookmark